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Abstract: The aim of this project was to examine the effect of microneedle rollers on the percutaneous
penetration of tiagabine hydrochloride and carbamazepine across porcine skin in vitro. Liquid
chromatography-mass spectrometric analysis was carried out using an Agilent 1200 Series HPLC
system coupled to an Agilent G1969A TOF-MS system. Transdermal flux values of the drugs
were determined from the steady-state portion of the cumulative amount versus time curves.
Following twelve hours of microneedle roller application, there was a 6.74-fold increase in the
percutaneous penetration of tiagabine hydrochloride (86.42 ± 25.66 µg/cm2/h) compared to passive
delivery (12.83 ± 6.30 µg/cm2/h). For carbamazepine in 20% ethanol, passive transdermal flux of
7.85 ± 0.60 µg/cm2/h was observed compared to 10.85 ± 0.11 µg/cm2/h after microneedle treatment.
Carbamazepine reconstituted in 30% ethanol resulted in only a 1.19-fold increase in drug permeation
across porcine skin (36.73 ± 1.83 µg/cm2/h versus 30.74 ± 1.32 µg/cm2/h). Differences in flux values
of untreated and microneedle-treated porcine skin using solid microneedles for the transdermal
delivery of tiagabine were statistically significant. Although there were 1.38- and 1.19-fold increases
in transdermal flux values of carbamazepine when applied as 20% and 30% ethanol solutions across
microneedle-treated porcine skin, respectively, the increases were not statistically significant.
Keywords: epilepsy; carbamazepine; tiagabine hydrochloride; transdermal drug delivery; microneedles
1. Introduction
The transdermal route of drug administration is advantageous because it avoids shortcomings
of oral drug delivery [1]. The advantages of the percutaneous route include painlessness, avoidance
of first pass metabolism and the absence of erratic absorption, control over the rate of drug release,
easy termination of therapy, and the possibility of self-administration and sustained drug release with
a single application [2–4]. Despite the obvious advantages of this route of drug administration, only
about 20 active pharmaceutical ingredients are used in clinical practice in the form of transdermal
patches [5–7]. This is because the skin forms a remarkably strong barrier against drug penetration [8].
Percutaneous transport of drug molecules across the skin is challenging because of the structure and
components of the skin [8]. The human skin protects the internal organs and permits extremely low
drug absorption from the skin surface.
The stratum corneum (SC) hinders transdermal drug delivery [9]. Although 10 to 25 layers of
corneocytes provide the physical barrier, corneodesmosomes hold the corneocytes together in an
equimolar ratio mixture of ceramides, cholesterol, and free fatty acids [9–11]. Percutaneous drug
penetration is achieved by either diffusion through the epidermis or through the skin appendages
(i.e,. sweat glands and hair follicles) [9]. In healthy skin, lipid composition plays an important
role in permeability due to its unique organization, where lipid sheets are stacked parallel to the
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skin surface [11]. Several techniques are available for enhancing drug absorption through the
skin. These include iontophoresis [12], sonophoresis [13], chemical penetration enhancers [14] and
microneedles [15].
Microneedles are micron-sized needles with lengths ranging from 100 up to 1000 µm. These devices
are capable of facilitating the delivery of drugs across the skin by creating micron-sized pores through
the stratum corneum without causing pain or bleeding [16]. The unique structure and geometry of
microneedles influence the rate at which drugs diffuse through the skin. These factors include needle
length, density, shape, and size in addition to the number of applications and the concentration of
drug used [16,17]. The needles must be strong enough to penetrate the tough skin barrier while
withstanding the pressure required during insertion [18]. Microneedles are especially important
for patients with needle phobias [19,20]. Although microneedle technology has been available for a
number of years, it is increasingly being used for the delivery of new compounds and the products of
the biotechnological industry. It has been shown that microneedles can be used to deliver proteins,
peptides and small interfering RNAs (siRNAs). MNs are minimally invasive and can be administered
without damaging nerve endings in the skin [21]. The use of MNs is preferred because these devices
are inexpensive and offer more reliable mode of administration by improving the pharmacokinetic and
pharmacodynamics profiles of drugs [21]. MNs induce faster healing at administration site compared
to hypodermic needles while allowing for a controlled rate of drug delivery [22]. Passive approaches,
such as penetration enhancers, result in skin irritation and are limited to only small molecules [6,21].
Other active methods, including electroporation, iontophoresis, magnetophoresis, and sonophoresis,
generally require expensive and complex systems [21].
Microneedle rollers continue to attract research interest [23,24]. It is a simple and cost-effective
technique to increase transdermal delivery of medications applied to the skin [25]. Microneedle rollers
contain micron-sized solid needles that are symmetrically aligned on a cylindrical surface, allowing
a rolling movement as it is pushed along the skin surface [17,23,25,26].
Epilepsy is a chronic neurological disorder in which patients experience repeated seizures or
excessive amounts of electrical discharges in brain cells [27]. This disorder involves at least two
unprovoked seizures occurring more than 24 h apart [28]. Although the etiology of epilepsy is still
unclear, it has been postulated that epilepsy involves diverse biological pathways and mechanisms [29].
It is thought that this disorder results from the imbalance of neurotransmitters, specifically glutamate
and γ-aminobutyric acid (GABA) [30,31]. Progression of epilepsy results when glutamate concentration
is high, causing an increase in Ca2+ uptake and generation of frequent depolarization in neurons [32].
GABA, contrarily, maintains the balance of neuron excitation and restricts presynaptic potentials
through the hyperpolarization of neurons. [33]. GABAA receptors are ligand-gated ion channels
that promote rapid inhibition of presynaptic action potentials by accumulating Cl− concentration in
neurons [29]. GABAB receptors are G-protein-coupled receptors that function similarly to GABAA
receptors but instead induce slow inhibition by increasing K+ and decreasing Ca2+ flow into neural
cells [29]. In recent studies, serotonin neurotransmitters have also shown to play an important role
because of their presence on neurons in the brain. Serotonin is also known as 5-hydroxytryptamine
(5-HT) and is able to limit neuronal excitability by activities of various 5-HT subtypes [29].
One of the widely used drugs for the management of epilepsy is carbamazepine (Figure 1a).
Carbamazepine (CBZ) has a molecular weight 236.27 g/mol and is a first-choice antiepileptic drug
due to few adverse effects [34]. Sold under brand name Tegretol®, the drug is a dibenzazepine tricyclic
compound that functions as a sodium channel blocker [35,36]. CBZ acts postsynaptically by blocking
voltage-gated sodium channels, resulting in the restriction of repetitive firing of action potentials [34,37].
Recent studies have shown that CBZ inhibits the N-methyl-D-aspartate (NMDA) subtype of glutamate
receptor while pumping K+ out of neurons and stabilizing inactive Na+ channels with high binding
rate constant [38,39]. Inhibition of NMDA receptors is the main antiepileptic property of CBZ because
cations are not able to enter neurons. The restriction of cation entry prevents neural depolarization of
action potentials.
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Figure 1. Chemical structures of (a) carbamazepine and (b) tiagabine. 
Conventionally, transdermal drug delivery research is usually restricted to low-dose, potent 
compounds with optimal physicochemical properties [40]. Recently, though, more research 
laboratories are devoting considerable time and effort to the development of transdermal drug 
delivery systems for high dose compounds such as ibuprofen sodium [41] and carbamazepine 
prodrugs [42]. The rationale for this development is that most medications are high dose, low potency 
compounds [43]. It is well established that many drugs require high daily doses to obtain therapeutic 
plasma concentrations [43]. There is therefore an unmet need for enhancement techniques with the 
potential of delivering high dose medications across the skin. This was the scientific basis upon which 
we embarked on the transdermal delivery of carbamazepine. 
Another drug used for the management of epilepsy is tiagabine (Figure 1b). The drug finds 
clinical application as an add-on therapy for patients over the age of 12 with partial epilepsy that has 
not been successfully managed by other antiepileptic drugs [44]. The drug has a molecular weight 
412.01 g/mol and acts by inhibiting presynaptic uptake of GABA neurotransmitters in the brain at the 
synaptic cleft [45]. Limiting uptake of GABA at the presynaptic neurons results in more GABA 
present for receptor binding to postsynaptic neural cells. In fact, GABA unlocks chloride channels on 
neurons, allowing hyperpolarization of neuronal cell membranes [46]. The use of tiagabine has two 
benefits: higher physiological specificity where only released GABA is affected, and reduction of 
possible side effects [44]. Temporary inhibition of GABA neurotransmitters is currently the only 
known mechanism of action of tiagabine [39]. 
Antiepileptic drugs are generally available as tablets for oral administration, but this can pose 
problems for patients who are unable to consume medications orally [47]. These patients may have 
difficulty in swallowing, may be in coma or may have gastrointestinal discomfort [22]. Patient 
compliance may be a problem for those who cannot tolerate the taste of oral medications. 
Additionally, polypharmacy can be an issue, especially in the elderly population, causing 
noncompliance and forgetfulness due to the requirement of frequent dosing. Transdermal drug 
delivery is useful in such cases [17,48,49]. 
The purpose of our research was to investigate the effect of microneedle rollers on the 
percutaneous penetration of two antiepileptic drugs, carbamazepine and tiagabine hydrochloride, 
across pig skin. Pig skin is inexpensive and can be used as a surrogate for human skin [50]. According 
to Flaten et al., stratum corneum thickness, viable epidermis, and hair follicle and density parameters 
between porcine and human skin are within the ranges of one another[50]. The use of human skin is 
ethically challenging despite being considered as the “golden standard” in drug diffusion studies 
[51,52]. Pig ear skin was porated with stainless steel microneedle rollers and the transdermal flux of 
drugs was monitored. 
2. Materials and Methods 
2.1. Materials 
Phosphate buffer saline (PBS, 0.1 M, pH 7.4), ethanol, propylparaben, tiagabine hydrochloride, 
and carbamazepine were bought from Sigma Aldrich Co. (St. Louis, MO, USA). Tiagabine 
hydrochloride and carbamazepine were reconstituted in only PBS and PBS/ethanol mixture (20% and 
30% ethanol), respectively. Distilled ionized water was obtained from NanoPure Infinity Ultrapure 
water purification system (Barnstead, Dubuque, IA, USA). The length and density of the 
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Conventionally, transdermal drug d livery resea ch is usually restricted to low-dose, potent
compounds with optimal physicochemical properties [40]. Recently, though, more research laboratories
are devoting considerable time and effort to the development of transdermal drug delivery systems for
high dose compounds such as ibuprofen sodium [41] and carbamazepine prodrugs [42]. The rationale
for this development is that most medications are high dose, low potency compounds [43]. It is well
established that many drugs require high daily doses to obtain therapeutic plasma concentrations [43].
There is therefore an unmet need for enhancement techniques with the potential of delivering high
dose medications across the skin. This was the scientific basis upon which we embarked on the
transdermal delivery f carbamazepin .
A her dr g u ed for the management of epilepsy is tiagabine (Fi ure 1b). The drug finds
clinical application as an add-on therapy for patients over the age of 12 with partial epilepsy that has
not been successfully managed by other antiepileptic drugs [44]. The drug has a molecular weight
412.01 g/mol and acts by inhibiting presynaptic uptake of GABA neurotransmitters in the brain at the
synaptic cleft [45]. Limiting uptake of GABA at the presynaptic neurons results in more GABA present
for receptor binding to postsynaptic neural cells. In fact, GABA unlocks chloride channels on neurons,
allowing hyperpolarization of neuronal cell membranes [46]. The use of tiagabine has two benefits:
higher physiological specificity where only released GABA is affecte , and reduction of possible side
effects [44]. Temporary i hibiti n of GABA neurotransmitters is cu rently the only known ec nism
of action of tiagabine [39].
Antiepileptic drugs are generally available as tablets for oral administration, but this can
pose problems for patients who are unable to consume medications orally [47]. These patients
may have difficulty in swallowing, may be in coma or may have gastrointestinal discomfort [22].
Patient compliance may be a problem for those who cannot tolerate the taste of oral medications.
Additionally, polypharmacy can be an issue, especially in the elderly population, causing noncompliance
and forgetfulness due to the requirement of frequent dosing. Transdermal drug delivery is useful in
such cases [17,48,49].
The purpose of our research was to i vestigate the ffec of microneedle rollers on the
percutaneous penetrat on of two antiepileptic drugs, carbamazepine and tiagabine hydrochloride,
across pig skin. Pig skin is inexpensive and can be used as a surrogate for human skin [50]. According to
Flaten et al., stratum corneum thickness, viable epidermis, and hair follicle and density parameters
between porcine and human skin are within the ranges of one another[50]. The use of human
skin is ethically challenging despite being considered as the “golden standard” in drug diffusion
studies [51,52]. Pig ear skin was porated with stainless steel microneedle rollers and the transdermal
flux of drugs was monitored.
2. Materials and Methods
2.1. Materials
Phosphate buffer saline (PBS, 0.1 M, pH 7.4), ethanol, propylparaben, tiagabine hydrochloride, and
carbamazepine were bought from Sigma Aldrich Co. (St. Louis, MO, USA). Tiagabine hydrochloride
and carbamazepine were reconstituted in only PBS and PBS/ethanol mixture (20% and 30% ethanol),
respectively. Distilled ionized water was obtained from NanoPure Infinity Ultrapure water purification
system (Barnstead, Dubuque, IA, USA). The length and density of the microneedles on the microneedle
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Pig ears were purchased from Pel-Freez Arkansas LLC (Rogers, AR, USA). Upon arrival, ears
were shaved with an electric hair clipper. Full-thickness skins were obtained by using a scalpel to
remove subcutaneous fat from ear cartilage. An electric dermatome (Nouvag®, Goldach, Switzerland)
was used to prepare split-thickness skins. The thickness of the skin samples was determined with the
Digimatic micrometer (Mitutoyo, Tokyo, Japan). Skin membranes were wrapped in aluminum foil
and stored at −20 ◦C until ready for use. Experiments were approved by the Institutional Animal
Care and Use Committee (IACUC) and Institutional Biosafety Committee (IBC) of Touro University,
Mare Island-Vallejo, CA, USA.
2.2.2. Diffusion Studies
Microchannels were created on porcine skins using solid microneedle rollers and skin samples
were then clamped to the diffusion cells. The roller was applied to the pig ear skin 15 times (five times in
the vertical, horizontal and diagonal directions). The roller was applied with a force of 5 kg (measured
with a weighing balance) for approximately 1 min per application. Three microneedle-treated
split-thickness skin (STS) samples were used for the experiment while three untreated skin samples
served as controls. Diffusion experiments for tiagabine hydrochloride and carbamazepine were
replicated six times (n = 6). Each experiment was carried out using 1 mL of either tiagabine
hydrochloride (~5 mg/mL) or carbamazepine (~1 mg/mL). The compositions of formulations used in
this study are shown in Table 1. The drug was placed on porcine skin. The pig skin was sandwiched
between the donor and receptor compartments of Franz diffusion cells. The donor compartment
and covered with parafilm and aluminum foil to reduce evaporation. The sampling ports were also
sealed. Aliquots of 1 mL were taken using 1 mL syringes from the sampling port every 2 h for 12 h.
Extractions were stored in 2 mL amber vials from Agilent Technologies (Agilent, Santa Clara, CA,
USA) and stored at −8 ◦C until shipment to the University of Idaho for analysis. Receptor chambers
were replenished after each extraction with 1 mL of fresh, pre-warmed PBS maintained at 37 ◦C.
We carried out in vitro diffusion studies with six vertical Franz Diffusion cells (PermeGear,
Hellertown, PA, USA). Each cell has donor compartments and receptor compartments. In each cell,
there is a magnetic stirrer, sampling port, and a water jacket maintained at a 37 ◦C model human body
temperature. The receptor compartment has a diffusion area of 1.77 cm2 and the volume is 12 mL.
The receptor compartment was filled with PBS, and we utilized high-vacuum grease (Dow Corning,
Midland, MA, USA) and a metal clamp to prevent loss of the drug solution through lateral diffusion.
Table 1. Formulations of tiagabine and carbamazepine used in the experiments.
Name of Solution Drug Concentration (mg/mL) Solvent(s) Solvent Volume (mL)
Tiagabine hydrochloride 5 Phosphate buffered saline (PBS) 7 mL PBS
Carbamazepine in 20% Ethanol 1 PBS + Ethanol 5.6 mL PBS + 1.4 mL Ethanol
Carbamazepine in 30% Ethanol 1 PBS + Ethanol 4.9 mL PBS + 2.1 mL Ethanol
2.2.3. HPLC/DAD/TOF-MS Analysis of Pharmaceuticals
HPLC analysis was performed using an Agilent 1200 Series HPLC system with a diode array
detection (DAD) system coupled to an Agilent G1969A TOF-MS system equipped with an ESI source
(Agilent, Santa Clara, CA, USA). The chromatographic analysis of tiagabine hydrochloride and
carbamazepine was performed using a Zorbax Eclipse Plus C18, 100 mm × 2.1 mm, 3.5 µm column
(Agilent, Santa Clara, CA, USA) maintained at 30◦ C. The injection volume was 5 µL. The mobile
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phase comprised of 0.1% formic acid in water (solvent A) and 0.1% formic acid in methanol (solvent
B). We first used a linear gradient from 15% to 95% B in 7 min, and then isocratic elution was carried
out at 95% B for 2 min. The final equilibration was conducted at 15% B for 5 min. We diverted the flow
from the mass spectrometer for the first 3 min of the analysis, in order to prevent MS contamination
and ion suppression. The flow rate was 0.3 mL·min−1.
Electrospray ionization was operated in the positive mode. The absolute values for electrospray
ionization potential and collision-induced dissociation potential were 3500 and 175 V, respectively.
Gas temperature was 350 ◦C, drying gas (N2) flow rate was 12 L·min−1, and nebulizer pressure
was 2.4 × 105 Pa. The analyses were conducted in a profile mode with an m/z ranged from 90 to
500 amu. Quantification was performed in the reconstructed ion current mode using m/z of 237.10
(carbamazepine), 376.14 (tiagabine), and 181.09 (propylparaben, used as internal standard).
2.2.4. Microchannel Visualization
Visualization of pores created by the microneedle roller was carried out with a Nikon
SMZ-745T dissecting microscope/zoom stereomicroscope (Nikon Instruments Inc., Melville, NY,
USA). Porcine skin samples were treated with a 500 µm microneedle roller for 5 s and then stained
for 1 min with either Fast Green FCF (Sigma Aldrich Co., St. Louis, MO, USA) or Alexa Fluor®
488 (Life Technologies, Eugene, OR, USA). Skin samples were then rinsed three times with 1 mL
portions of normal saline to remove excess dye and then blotted dry with Kimwipes (Kimberly-Clark
Professional, Roswell, GA, USA). Control skin samples were treated in the same manner but without
the use of microneedles. Images of both untreated and microneedle-treated skins were obtained
using a Nikon SMZ-745T dissecting microscope/zoom stereomicroscope equipped with a microscope
camera port and built-in 0.55x C-mount adapter for direct mounting of Nikon DS Series Digital Camera
(Nikon Instruments Inc., Melville, NY, USA).
2.2.5. Data Analysis
The average cumulative amount of drug permeation through porcine skin was plotted as
a function of time. Steady-state flux was calculated from the linear portion of the average cumulative
amount versus time curve. Six replicates were utilized for each drug. Sampling effects were taken into











In the Hayton–Chen equation, C1n is the corrected concentration and Cn is the measured
concentration in the nth sample. VT represents the total volume of the receiver fluid (12 mL) and VS is
the volume of sample withdrawn from the receiver fluid (1 mL). C1n−1 and Cn−1 are the corrected and
measured concentration, respectively, in the (n−1)th sample.
2.2.6. Statistical Analysis
Statistical analysis was performed using GraphPad Prism 7 (GraphPad Software, Inc., La Jolla,
CA, USA). The Mann–Whitney Rank Sum test was carried out to determine statistical significance.
A p-value of less than 0.05 was considered statistically significant. The average of replicate
measurements (n = 6) with corresponding standard deviation was used to plot the graphs.
3. Results
3.1. Microchannel Visualization
Microneedles were used to disrupt the stratum corneum barrier and enhance transdermal drug
delivery. Figure 2 shows the pores created by the microneedle roller on full-thickness skin compared
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to untreated porcine skin after staining. The pores (Figure 2B,D) were identified as the openings filled
with either Fast Green FCF (Figure 2B) or Alexa Fluor® 488 (Figure 2D). Fluorescence was viewed using
the NIGHTSEA™ add-on light and filter set with royal blue color light head (Electron Microscopy
Sciences, Hatfield, PA, USA). The skin surrounding the microchannels remained intact without any
tear in the stratum corneum. Figure 2B,D show the symmetrically aligned pores that imitate the
pattern of the needles on the roller itself. Untreated porcine skins were utilized as control samples
(Figure 2A,C) to confirm that the microchannel patterns on the skin surface resulted from microneedle
application. Very few reports have examined the kinetics of micropore closure following microneedle
application [69]. However, it has been documented that following the use of microneedles in humans,
pores may close as quickly as 15 min or as long as several hours [69].
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Figure 2. Microchannel visualization using Fast Green FCF on (A) untreated skin and
(B) microneedle-treated skin; Alexa Fluor® 488 on (C) untreated skin and (D) microneedle-treated skin
using 7.5× magnification.
3.2. In Vitro Transdermal Drug Delivery
The cumulative amounts per hour of both tiagabine hydrochloride (Figure 3A) and carbamazepine
in 20% and 30% ethanol (Figures 4A and 5A, respectively) are higher after microneedle application
when compared to untreated skin. In vitro percutaneous flux of tiagabine hydrochloride increased from
12.83 ± 6.30 µg·cm2·h across untreated skin to 86.42 ± 25.66 µg·cm2·h across microneedle-treated skin,
as shown in Figure 3B. Although we did not specifically measure resistance in our experiments, several
reports in the literature indicate that transcutaneous flux increases can be correlated with decreased
skin resistance. Carbamazepine reconstituted in 20% ethanol (Figure 4B) showed a rise in flux from
7.85 ± 0.60 µg·cm2·h to 10.85 ± 0.11 µg·cm2·h. Lastly, the total flux for carbamazepine dissolved in
30% ethanol across microneedle-treated porcine skin (Figure 5B) was 36.73 ± 1.83 µg·cm2·h compared
to 30.74 ± 1.32 µg·cm2·h across untreated skin. Transdermal fluxes of tiagabine hydrochloride and
carbamazepine in 20% and 30% ethanol for untreated and microneedle-treated skins are summarized
in Table 2. Remarkably, there was no flux increase for CBZ. This is not surprising, as there are reports
in the literature showing that the flux of poorly soluble and hydrophobic compounds may not always
be enhanced. For example, Vitorino and coworkers did not observe significant transdermal flux
enhancement of simvastatin or olanzapine after application of nanostructured lipid carriers [68].
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Table 2. Transdermal flux (µg/cm2/h ± SD) of tiagabine hydrochloride and carbamazepine in 20%
and 30% ethanol following treatment with a 500 µm microneedle roller. Passive flux values served as
controls (n = 6).
Name of Solution Passive (µg/cm2/h) Microneedle (µg/cm2/h) Flux Increase p-Value
Tiagabine hydrochloride 12.83 ± 6.30 86.42 ± 25.66 6.74 0.039
Carbamazepine in 20% ethanol 7.85 ± 0.60 10.85 ± 0.11 1.38 0.138
Carbamazepine in 30% ethanol 30.74 ± 1.32 36.73 ± 1.83 1.19 0.219
4. Discussion
Tiagabine hydrochloride has a molecular weight of 412.01 Daltons. The partition coefficient of
the compound is 2.6 and the melting point is 193–195 ◦C. With an aqueous solubility of 10 mg/mL,
tiagabine hydrochloride readily dissolves in phosphate buffer saline, pH 7.4. It has been documented
that the therapeutic drug concentration is 20–200 ng/mL, and patients are advised to take less than
56 mg/day [54,55].
The compound is instantaneously absorbed in the gastrointestinal (GI) tract around 30 to 90 min
after oral administration with 90% bioavailability and elimination half-life of 5 to 9 h [44]. After drug
administration, tiagabine can readily cross the blood–brain barrier and mainly localizes in the cerebral
cortex and hippocampus [39]. Passing through the blood–brain barrier is made possible since tiagabine
is an analogue of nipecotic acid that is attached to a lipophilic anchor [39]. Volume of distribution is
1 L/kg and less than 1% is unchanged when excreted as urine [42].
Carbamazepine has a partition coefficient of 2.7 ± 0.3 and a melting point of 189 ± 0.71 ◦C
with aqueous solubility of 440.6 ± 20.6 µg/mL at 32 ◦C in phosphate buffer saline of pH 7.4 [42].
The compound’s molecular weight is 236.27 Daltons. Carbamazepine has a low aqueous solubility
and, therefore, was reconstituted in a mixture of ethanol and phosphate buffer saline. Even though the
use of microneedles does not always lead to transdermal flux enhancement [56], Gomaa et al. have
observed that microneedle-assisted transdermal delivery of drugs with unfavorable skin absorption
properties has the potential of bringing to clinical practice more effective and safer products [57]. It was
important to evaluate in the present study, if indeed microneedles will facilitate the percutaneous
penetration of CBZ.
The oral dose of CBZ in adult patients ranges from 400 to 2000 mg/day, with 400 mg being
a recommended dose for most patients [58,59]. Dosages are generally adjusted according to age
and severity of epilepsy to obtain optimal therapeutic doses. The therapeutic drug concentration of
CBZ ranges between 4 and 12 mg/L [60]. Bioavailability is approximately 75%–85% and half-life
is 10–20 h [59]. Volume of distribution is 0.5–2 L/kg and clearance 0.112 ± 0.0147 L/h/kg [61,62].
Interestingly, more exposure to CBZ leads to faster half-life and clearance. Because CBZ is lipid soluble,
it slowly breaks down in the gastrointestinal (GI) fluid. CBZ is metabolized in the liver, forming
several metabolites including carbamazepine-10,11-epoxide [35,63]. Only 1% of CBZ is excreted in
urine unchanged [59].
Typically, the compounds delivered by microneedles have high potency, meaning only a low
dose is required to achieve a therapeutic effect [41]. From the clinical standpoint, the majority of
commercially available active pharmaceutical ingredients are not low dose high potency molecules.
In the contemporary clinical setting, many medications require daily oral doses of several hundred
milligrams [41]. The percutaneous route of drug administration has conventionally been used for
relatively lipophilic, low molecular weight and potent medications. Because most drug molecules do
not have these optimal properties, commercially available transdermal patches have been developed
from about 20 active pharmaceutical ingredients [41]. Indeed, the transdermal drug delivery route has
proved efficacious for a number of medications used in the management of neurological disorders.
For instance, rotigotine is delivered in therapeutic concentration from the transdermal drug delivery
system (Neupro®) [25]. In addition, the transdermal delivery route bypasses and avoids the substantial
hepatic first pass metabolism observed with the oral medication. To deliver high dose medications,
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some research laboratories have developed specific reservoir-based microneedle systems. One of these
systems was reported by McCrudden and coworkers [41].
Another interesting consideration is that several innovative microneedle systems are being
developed daily. However, it does not matter how sophisticated these systems are if they do not deliver
therapeutic doses of medications. There are also several mathematical models to describe and/or
predict the skin permeation of drugs from microneedles [64]. However, only experiments can validate
transcutaneous flux values of medications. We took into consideration the above-mentioned facts
when we chose two different antiepileptic agents, tiagabine hydrochloride and carbamazepine, for our
research project. The results of this project will guide our future development of microneedle systems.
In our study, we showed that the application of microneedle rollers led to increased flux values of
tiagabine hydrochloride. To our knowledge, this is the first time that microneedle-assisted delivery
of tiagabine hydrochloride has been investigated. However, it is noted that developments of a
transdermal patch for tiagabine hydrochloride is currently in its preclinical stage [65]. A US patent
(US 5750140 A) was also filed in 1998 for this transdermal drug delivery system [66]. Percutaneous
penetration of carbamazepine has been previously studied by Fourie et al. In their study, the authors
showed that the steady state flux value for carbamazepine was 3.29 ± 0.64 µg·cm2·h across untreated
epidermal tissue [42]. Our present study recorded transdermal flux values across untreated porcine
skin as 7.85 ± 0.60 and 30.74 ± 1.32 µg·cm2·h for carbamazepine reconstituted in 20% and 30% ethanol,
respectively. Numerous factors can cause a lack of transdermal flux enhancement, which we observed
in this project. The physicochemical properties of a drug can influence the rate of transdermal drug
penetration. Hoang et al. alluded to the fact that low diffusion coefficient can lead to low flux values [24].
Carbamazepine is a high dose molecule and although the transdermal drug delivery potential of
this drug has been investigated, our knowledge of the factors influencing percutaneous penetration
of this compound is still poor. Fourie and coworkers, for instance, used full-thickness skin (FTS)
obtained from the abdomen of female patients to study the transcutaneous penetration of CBZ [42].
The epidermal layers were then separated from excess fat layers by immersing skin samples in 60 ◦C
water prior to use. The authors prepared carbamazepine solutions in phosphate buffer saline (PBS)
without addition of ethanol. For our study, we prepared split-thickness (STS) porcine ear skins using a
dermatome to achieve skin thicknesses of 757 ± 80 µm and 857 ± 90 µm for 20% and 30% ethanol,
respectively. Porcine skin is an inexpensive and ideal substitute for human skin due to many similarities
of the skin layers [50]. According to Flaten et al., stratum corneum thickness, viable epidermis, and
hair follicle and density parameters between porcine and human skin are within the ranges of one
another. The use of human skin is generally not feasible and unethical, despite being considered as the
“golden standard” in drug diffusion studies [50,67]. We reconstituted carbamazepine in an ethanol
and PBS mixture to increase the drug’s solubility. Ethanol diffuses through the skin and improves
the permeability of the SC by interfering with the lipid matrix [51]. In addition, 20% and 30% ethanol
ratios were chosen because ethanol concentrations greater than 40% may affect the SC barrier function
due to possible back-diffusion and enzymatic degradation [50].
It is well established that the use of microneedles [52] and other penetration enhancers (physical
and chemical) can lead to transdermal drug delivery flux enhancement. However, there are
instances where flux enhancement is not demonstrated [68]. As an example, Vitorino et al. did
not observe significant transdermal flux enhancement of simvastatin or olanzapine after application of
nanostructured lipid carriers [68]. The authors attributed low permeation to poor solubility and the
hydrophobicity of the investigated compounds. Low solubility may also be responsible for the low
penetration of CBZ observed in our study. Even though ethanol was effective in increasing the flux of
simvastatin and olanzapine in the study by Vitorino and coworkers [68], no statistically significant
enhancement effect was observed in our study. This may be attributed to the fact that ethanol has
a well-known carry-in effect, which is efficient initially but does not persist due to quick disappearance
of ethanol by evaporation and fast diffusion.
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5. Conclusions
The use of solid microneedles has a significant influence of the transdermal delivery of tiagabine
hydrochloride. Our results demonstrated a statistically significant enhancement in the flux of
tiagabine hydrochloride, showing a 6.74-fold increase after microneedle application. Conversely,
we determined that the differences in the transcutaneous flux of carbamazepine across untreated and
microneedle-treated skins were not statistically significant.
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